RBC Capital analyst Leonid Timashev lowered the price target on Axsome Therapeutics (NASDAQ: AXSM) to $130.00 (from $131.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Axsome Therapeutics (AXSM) PT Lowered to $180 at H.C. WainwrightAugust 6, 2024 6:37 AM BofA Securities Upgrades Axsome Therapeutics (AXSM) to BuyAugust 6, 2024 6:07 AM Form S-8 Axsome Therapeutics, August 5, 2024 4:37 PM Form 10-Q Axsome Therapeutics, For: Jun 30August 5, 2024 4:32 PM Form 8-K Axsome Therapeutics, For: Aug 05August 5, 2024 7:06 AM Axsome Therapeutics (AXSM) Misses Q2 EPS by 36c, offers guidanceAugust 5, 2024 7:03 AM Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 5, 2024 7:00 AM